ArticleBMC pulmonary medicine2026
Nitric oxide exacerbates systemic inflammation in adults with severe acute respiratory.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInhaled nitric oxide (iNO) is used as rescue therapy for severe acute respiratory distress syndrome (ARDS), but its dose-dependent effects on systemic inflammation and outcomes remain controversial. This study aimed to compare clinical outcomes between high- and low-dose iNO in adults with severe ARDS.
methodsIn this single-center retrospective cohort study, 117 patients with severe ARDS (PaO₂/FiO₂ ≤100 mmHg) treated with iNO between January 2020 and July 2024 were categorized by the maximum iNO concentration received: high-dose (≥ 10 ppm, n = 59) and low-dose (< 10 ppm, n = 58). Baseline characteristics, inflammatory markers (white blood cells, interleukin-6 [IL-6], tumor necrosis factor-α [TNF-α]), thromboelastography maximum amplitude (MA) value, Sequential Organ Failure Assessment (SOFA) score, vasopressor requirement, and 30-day survival were analyzed.
resultsBaseline characteristics were balanced between groups. Compared to the low-dose group, the high-dose group had significantly higher levels of inflammatory markers (WBC, IL-6, TNF-α; all P < 0.001), lower MA values (P < 0.001), higher SOFA scores (P = 0.031), greater norepinephrine requirements (P = 0.026), longer mechanical ventilation duration (P < 0.001), and fewer 30-day survival days (P < 0.001). Receiver operating characteristic curve analysis indicated good discriminatory power (AUC > 0.7) for these parameters in identifying high-dose exposure. Kaplan-Meier analysis showed significantly worse 30-day survival in the high-dose group (Log-rank P = 0.019).
conclusionsIn this retrospective cohort, high-dose iNO (≥ 10 ppm) was associated with exacerbated systemic inflammation, impaired coagulation function, greater organ dysfunction, and increased 30-day mortality compared to low-dose iNO in severe ARDS. These findings suggest cautious use of higher iNO concentrations, emphasizing monitoring of inflammatory and coagulation responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.